We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche Acquires Verum Diagnostica, Leader in Platelet Function Testing

By LabMedica International staff writers
Posted on 12 Dec 2011
Roche (Basel, Switzerland) will acquire 100% of Verum Diagnostica GmbH, based in Munich (Germany). More...
Verum Diagnostica is a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market. The company will become part of Roche's Professional Diagnostics business area.

Under the terms of the acquisition agreement, Roche will pay Verum Diagnostica shareholders a total cash consideration of EUR 11 million and potentially a further EUR 2 million contingent upon reaching certain performance-related milestones. The transaction is subject to customary closing conditions and is expected to close in January 2012.

The acquisition supports Roche's plans to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of coagulation analyzers for hospital and reference laboratories. The new line is expected to be introduced in the United States and Canada in 2014, subject to regulatory approval and other requirements.

Verum Diagnostica GmbH is a 100% subsidiary of Dynabyte Informationssysteme GmbH, developing, producing, and marketing the Multiplate analyzer. Multiplate is one of the most widely applied platelet aggregometers in Europe. Using simple whole blood analysis and intuitive software, the instrument is easy to implement in routine laboratory and near patient environments. Multiplate is the method of choice for many European and international centers and is regarded by many experts as the analyzer best suited for the clinical monitoring of antiplatelet therapy.

Dynabyte also produces test cells and reagents for the determination of platelet function in whole blood for use in hospital laboratories and near-patient settings, such as interventional cardiology, surgery, and intensive care.

"Improving the assessment of a patient's platelet function status is currently a significant unmet need for hematologists, cardiologists and anesthetists in order to support clinical decisions in cardiology, surgery, and intensive care," said Colin Brown, Head of Roche Professional Diagnostics.

Related Links:

Roche
Verum Diagnostica



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.